Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity

NCT03096288 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03096288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03096288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity
Lead sponsor
University of Florida
Phase
Phase 4
Overall status
Completed
Start date
October 3, 2017
Completion date
November 2, 2020
Enrollment
259 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease